Seegene, 197,441 Shares Net Sold by Individuals in Last 5 Days... Stock Price 281,200 KRW (+1.85%)
As of 2:31 PM on the 7th, Seegene is trading at 281,200 KRW, up 1.85% from the previous day. The trading volume is 885,253 shares, which is 98.64% of the previous day's volume. Seegene is known as a company that develops, manufactures, and sells molecular diagnostic reagents.
On September 29, researcher Lee Dal-mi of SK Securities forecasted that "the company's performance growth is expected to continue until next year. First, in preparation for the colder weather, the export approval for a diagnostic kit capable of simultaneously diagnosing seasonal flu and COVID-19 was obtained this month and is scheduled to be launched soon. Additionally, with an increase in equipment sales, performance improvements are expected not only for COVID-19 but also for other respiratory diagnostic kits, so the growth trend is expected to continue until 2021." Lee set Seegene's target price at 330,000 KRW.
Over the past five days, individual investors have net sold 197,441 shares of Seegene, while foreigners and institutions have net bought 142,759 shares and 60,685 shares, respectively.
Hot Picks Today
"Heading for 2 Million Won": The Company the Securities Industry Says Not to Doubt [Weekend Money]
- "Anyone Who Visited the Room Salon, Come Forward"… Gangnam Police Station Launches Full Staff Investigation After New Scandal
- "Can't Even Turn On a Fan? How Will They Endure the Heat?"... Massive Blackout Hits the Philippines Amid Scorching Heat
- "Drink Three Cups of Coffee and Stay Up All Night Before the Test"... Manual of Insurance Planner Who Collected 1 Billion Won in Payouts
- Did Samsung and SK hynix Rise Too Much?... Foreign Assets Grow Despite Selling [Weekend Money]

※Source: AI Investment Assistant AI Rassiro
※ This article was generated in real-time by an automatic article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.